Clinical Trial Update: The Use of Trifluoperazine in Transfusion Dependent DBA [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of trifluoperazine for transfusion-dependent Diamond Blackfan Anemia and Pure Red Cell Aplasia was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diamond-blackfan Anemia
• Pure Red Cell Aplasia

Drugs mentioned

• trifluoperazine (trifluoperazine)

Snippet

Sponsor: Adrianna Vlachos, MD | Conditions: Diamond Blackfan Anemia, Pure Red Cell Aplasia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-12-14